COvera in BRAnch Registry

November 10, 2022 updated by: Bertoglio Luca, IRCCS San Raffaele

A Physician-initiated, Multicentre, Ambispective, Observational Registry of Patients Undergoing Complex Aortic Procedures With the Use of the Bard Covera Plus (Tempe, Arizona, USA) Covered Self-expandable Stents

The purpose of the registry is to evaluate the peri-operative and short-, mid- and long-term outcomes of the Bard Covera Plus (Tempe, Arizona, USA) for the treatment of atherosclerotic aorto-iliac aneurysm in combination with a multibranched endograft

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hamburg, Germany
        • University Heart & Vascular Center
      • Munich, Germany
        • Ludwig-Maximilians University Hospital
      • Asti, Italy
        • Ospedale di Asti
      • Avellino, Italy
        • Ospedale Giuseppe Moscati
      • Bari, Italy
        • Azienda Ospedaliero Universitaria Consorziale Policlinico
      • Brescia, Italy
        • Fondazione Poliambulanza
      • Cosenza, Italy
        • Azienda Ospedaliera di Cosenza
      • Cuneo, Italy
        • Azienda Ospedaliera Santa Croce e Carle
      • Firenze, Italy
        • Ospedale Civile San Giovanni di Dio
      • Genova, Italy
        • Ospedale Policlinico San Martino
      • Messina, Italy
        • Azienda Ospedaliera Universitaria Gaetano Martino
      • Milan, Italy, 20132
        • IRCCS San Raffaele
      • Milan, Italy
        • Ospedale Niguarda
      • Modena, Italy
        • Azienda Ospedaliera di Modena
      • Napoli, Italy
        • Ospedale Cardarelli
      • Padova, Italy
        • Azienda Ospedaliera di Padova
      • Palermo, Italy
        • Ospedale Civico
      • Parma, Italy
        • Azienda Ospedaliera Universitaria di Parma
      • Peschiera Del Garda, Italy
        • Ospedale Pederzoli
      • Reggio Emilia, Italy
        • Arcispedale Santa Maria Nuova
      • Roma, Italy
        • Policlinico Umberto I
      • Roma, Italy
        • Ospedale San Filippo Neri
      • Roma, Italy
        • Policlinico Gemelli
      • Roma, Italy
        • Ospedale San Camillo
      • Roma, Italy
        • Ospedale San Giovanni Addolorata Britannico
      • San Giovanni Rotondo, Italy
        • Ospedale Casa Sollievo della Sofferenza
      • Torino, Italy
        • Ospedale Molinette
      • Trento, Italy
        • Ospedale Santa Chiara
      • Treviso, Italy
        • Ospedale Santa Maria di Ca' Foncello di Treviso
      • Trieste, Italy
        • Ospedale di Cattinara
      • Verona, Italy
        • Azienda Ospedaliera di Verona
      • Verona, Italy
        • Ospedale Borgo Roma
      • Vicenza, Italy
        • Ospedale San Bortolo di Vicenza

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

300 patients treated from January 2018 to January 2022 for atherosclerotic aorto-iliac aneurysm with procedures requiring the use of the Covera Plus covered stent in combination with a branched endograft

Description

Inclusion Criteria:

  • Adult patients ≥18 years
  • Patients who underwent/will undergo a complex aortic procedure with the use of a Covera Plus covered stent graft as a bridging stent, in the centres involved in this Registry
  • Subject has consented for study participation and signed the approved Informed Consent

Exclusion Criteria:

  • Bleeding diathesis or coagulopathy
  • Patients with active systemic or cutaneous infection or inflammation
  • Patients who are pregnant or lactating
  • Patient younger than 18 years of age
  • Patients who did not receive treatment using a Covera Plus covered stent graft.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Covera Plus
atherosclerotic aorto-iliac aneurysm

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
technical success
Time Frame: 30 days
freedom from type I or type III endoleak, stenosis/occlusion, dislocation/kinking
30 days
Branch instability
Time Frame: 30 days
freedom from branch-related complications
30 days
Primary clinical success
Time Frame: 30 days
freedom from death, type I/III endoleak, graft infection/thrombosis, aneurysm expansion and/or rupture, conversion to open repair, or new treatment-related thoraco-abdominal pathologies
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 16, 2020

Primary Completion (ACTUAL)

October 30, 2022

Study Completion (ACTUAL)

October 30, 2022

Study Registration Dates

First Submitted

October 16, 2020

First Submitted That Met QC Criteria

October 21, 2020

First Posted (ACTUAL)

October 22, 2020

Study Record Updates

Last Update Posted (ACTUAL)

November 14, 2022

Last Update Submitted That Met QC Criteria

November 10, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • COBRA Registry

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aneurysm

Clinical Trials on covered stent

3
Subscribe